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Abstract
Background: Neurocognitive impairment is frequently described in a number of psychiatric
disorders and may be a direct consequence of serotonergic dysfunction. As impairments in
executive functions are some of the most frequently described, the purpose of this study was to
examine the performance of normal volunteers on a range of executive tasks following a transient
reduction of central serotonin (5-HT) levels using the method of acute tryptophan depletion
(ATD).
Methods: Fifteen healthy male subjects participated in a within-subject, double-blind,
counterbalanced crossover study. ATD was induced by ingestion of a 100 g amino-acid drink.
Executive function was evaluated using the Wisconsin Card Sorting Test, Stroop, Verbal Fluency
and Trail Making. Visual analogue scales were administered to assess mood.
Results: Plasma free and total tryptophan concentrations were significantly reduced by the
depleting drink (P < 0.001). ATD selectively improved motor speed/ attention on the Trails A test
(P = 0.027), with no effect on subjective ratings of mood. Interaction effects between drink and the
order of drink administration were observed on most neurocognitive tests.
Conclusions: The improvement in simple motor speed/ attention following ATD is in keeping
with the ascribed role of 5-HT in the cortex, however performance on tests of executive function
is not robustly altered. The presence of interaction effects on most tasks suggests that subtle
changes may occur but are masked, possibly by simple learning effects, in the context of a crossover
design. This has implications for the design of future studies, particularly those examining executive
functions.
Background
Serotonin (5-hydroxytryptamine; 5-HT) systems are
widely distributed throughout the central nervous system.
The existence of specific pathways projecting from the
raphé nuclei to the forebrain and the density of 5-HT
receptors in these and other areas, such as the
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body of evidence implicating 5-HT in the processes of
learning and memory [1,2].
Interest has focused on the serotonergic system not only
because of its ascribed role in normal neurocognitive
functioning, but because of the implication that 5-HT sys-
tems may be compromised in many psychiatric disorders
[3] including, schizophrenia [4], bipolar disorder [5] and
major depression [6]. It has been established that neuro-
cognitive impairment is a core feature of these disorders
[7–9] and this may, in part, be a consequence of seroton-
ergic dysfunction.
While the pattern and magnitude of impairment in these
disorders is diverse and dependent upon many factors,
including clinical state at the time of testing, previous
studies have frequently reported impairments in executive
functioning [10–12]. Executive functions are 'higher-
order' cognitive processes involved in planning, judge-
ment, decision-making, anticipation or reasoning, and are
responsible for the control of attention, inhibition, set-
shifting and task management [13]. The neuroanatomical
locus of these processes is considered to be the frontal
lobes, specifically the prefrontal cortex, which over time,
has become synonymous with executive functioning
itself. However, it is now understood that such processes
activate diverse neural circuitry forming reciprocal frontal-
subcortical loops [14] and therefore that executive func-
tions are linked to, but not coterminous with, the opera-
tion of the frontal lobes [15,16]. Nevertheless, the known
innervation of 5-HT pathways to these sites suggests that
executive functions may be dependant upon the integrity
of the serotonergic system.
The precise role of the serotonergic system in cognition is
complex. Recent studies have suggested that a previously
proposed dichotomy – that stimulation of the 5-HT sys-
tem impairs learning and memory, whereas a reduction in
serotonergic function may enhance these processes –
requires reformulation as 5-HT1A, 5-HT2A, 5-HT2C/2B and
5-HT4 receptor antagonists do not consistently alter learn-
ing and memory in animals [17]. However, it is not clear
how reliably this can be translated to humans. Impair-
ments in spatial working memory have been demon-
strated following administration of the 5-HT agonist,
fenfluramine [18], and in list-learning following adminis-
tration of the partial 5-HT1A receptor agonist, buspirone,
accompanied by changes in regional cerebral blood flow
[19]. Clomipramine, a non-selective serotonin reuptake
inhibitor, has been shown to impair memory in patients
with depression [20] and panic disorder [21], however
this may be attributable to anti-cholinergic effects. In
some studies, single doses of SSRIs have been shown to
improve performance on choice reaction time tasks in
normal volunteers [22–24], although some of these
effects may occur though indirect actions involving other
neurotransmitter systems [25]. Alternatively, acute
administration of an SSRI through activation of pre-syn-
aptic 5-HT1A receptors may result in a net reduction in ser-
otonergic neurotransmission.
An alternative means of examining serotonergic involve-
ment in cognition is by selectively decreasing brain 5-HT
levels by the method of tryptophan depletion [26]. Acute
tryptophan depletion (ATD) using an amino acid drink
leads to around an 80 % depletion of plasma total and
free tryptophan (TRP), resulting in a moderate but signif-
icant reduction of central 5-HT metabolism [27]. We have
previously found impairments in executive function in
schizophrenia following ATD. Specifically, on the Wis-
consin Card Sorting Test, ATD led to a significant reduc-
tion in the number of categories completed but only when
the task is novel i.e. on the first visit. Tests of learning and
memory were unaffected [28].
In healthy volunteers the effects of ATD on executive func-
tions are not consistent. Park et al [29] found no evidence
directly implicating the 5-HT system in 'frontal lobe' func-
tions. Schmitt and colleagues have suggested that long-
term memory is impaired following ATD, while some
executive functions may be enhanced, such as verbal flu-
ency and focused attention [30]. ATD has been reported
to alter decision making in executive tasks, but this may be
the result of changes in impulsivity rather than an effect
on planning per se [31,32]. Other studies have failed to
find effects of ATD on any aspect of neuropsychological
function [33,34].
In the present study we sought to focus on the effects of
ATD on the WCST and a range of other tests of executive
function. Changes in subjective mood were also assessed.
As insufficient depletion may have been a contributory
factor in the lack of effects seen in our previous study [34]
we employed a more potent 100 g amino-acid drink.
Methods
Subjects
All subjects were recruited as part of a larger study exam-
ining the effects of ATD on EEG and neurocognitive func-
tion. The results of the EEG component of the study are
reported elsewhere [35]. Fifteen healthy male volunteers,
aged between 18 and 25 years (mean = 22.4, SD = 1.9
years) with a NART estimated IQ (National Adult Reading
Test; [36]) of between 90 and 118 (mean = 109, SD = 7.9)
and 14 to 19 years of education (mean = 16.7, SD = 1.8
years) participated in the study. All subjects were paid for
their participation. After full description of the study, writ-
ten informed consent was obtained. The study received
full approval from the local ethics committee.Page 2 of 9
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A within subject, double-blind, cross-over study was used.
Subjects attended the research unit at 0830 h following an
overnight fast and underwent baseline assessments. A 100
g amino acid drink was then administered. Subjects
received either the depleting or the control drink. Blood
samples for free and total TRP were taken at baseline and
5 hours after ATD or control drink. Between 6 and 7 hours
after consumption of the amino-acid drink, neuropsycho-
logical testing was carried out. After a minimum two-week
washout period, subjects returned for repeat testing with
the alternative drink. Nine subjects received the depleting
drink on their first visit, and 6 the control drink.
Drink Composition
Both drinks were of identical composition, with the
exception of the addition of 2.3 g of L-tryptophan to the
control drink. A 100 g amino acid drink was used [28,37],
the constituents being L-alanine 5.5 g, L-arginine 4.9 g, L-
cysteine 2.7 g, L-glycine 3.2 g, L-histidine 3.2 g, L-isoleu-
cine 8 g, L-leucine 13.5 g, L-lysine monohydrochoride 11
g, L-methionine 3 g, L-phenylalanine 5.7 g, L-proline 12.2
g, L-serine 6.9 g, L-threonine 6.5 g, L-tyrosine 6.9 g, L-
valine 8.9 g. This was mixed in 300 ml water, flavoured
with blackcurrant and sweetened with saccharin.
Biochemical Measures
Ten millilitres venous blood was taken on two separate
occasions during each experimental session. The blood
was added to anticoagulant and the plasma was immedi-
ately separated by centrifugation. A sample for free tryp-
tophan was further centrifuged using an ultra-filtrate tube.
All samples were stored at -20°C until assay. Plasma total
and free tryptophan was determined by High Pressure Liq-
uid Chromatography by the method of Marshall et al [38].
Subjective Mood Ratings
Subjective rating of mood was assessed using visual ana-
logue scales (VAS). The 16 scales used in the present study
condense into 3 factors: 'Alertness', 'Contentedness' and
'Calmness', which have been shown to be sensitive in the
measurement of drug effects [39].
Neurocognitive assessment
The Wisconsin Card Sorting Test (WCST) (PAR Inc [40])
This computerised test requires the subject to sort a
number of cards displaying either one, two, three or four;
red, green, yellow or blue; triangles, stars, crosses or circles
according to either number, colour, or shape of the sym-
bols on the card. The subject is not told which parameter
to sort by. After ten correct responses in a row, the sorting
principle changes. Thus, while the cards must be sorted
according to colour at the start of the test, the sorting prin-
ciple changes to 'shape', then to 'number' as the test
progresses. The test lasts until six blocks of ten correct
matches have been made or until a maximum of 128
cards have been presented.
Verbal Fluency (Benton's FAS; [41])
This is a test of verbal fluency which is sensitive to frontal
dysfunction [42]. There are 3 trials, each lasting 60 sec-
onds, in which subjects are required to list as many words
as possible, beginning with the given letters – 'F', 'A' and
'S' – excluding proper nouns or repetitions of the same
word with a different suffix. Performance is assessed by
the sum of acceptable words produced across the 3 trials.
Stroop Colour-Word Test [43]
This selective attention task is comprised of two trials.
Trial "C" requires subjects to read aloud a list of 112 col-
our names in which no name is printed in its matching
colour. In the subsequent "C-W" trial, subjects are
required to name the colour of ink in which the colour
names are printed. The colour-word score is considered a
measure of inhibitory control. Time to complete each trial
is recorded, and an interference index by subtracting trial
C from CW.
Trail-Making Test [44]
This test of visuo-motor speed and attention requires sub-
jects to join numbers in ascending order (part A), and
then alternate between letters and numbers (part B). Scor-
ing was the time (seconds) to complete each condition,
and a shift index derived by subtracting the time taken to
complete part A from part B.
Statistical Analysis
All descriptive statistics are presented as mean and stand-
ard deviation (SD). Changes in TRP levels were analysed
using paired t-tests. All mood scales and neurocognitive
tests were subjected to a mixed effects analysis of variance
(ANOVA) with 'drink' (ATD or control) as a within sub-
jects factor and 'order' of depletion (ATD first or control
first) as a between subjects factor. Where the assumptions
of the ANOVA were violated, data were subjected to loga-
rithmic (base 10) transformations (i.e. verbal fluency).
Post hoc analyses were carried out by t-test. The WCST
could not be transformed satisfactorily to achieve normal-
ity, therefore main effects and any post hoc analyses of sig-
nificant interactions were confirmed non-parametrically.
All analyses were performed using SPSS version 9 [45].
Results
Tryptophan levels
Complete sets of plasma samples were not available for
three subjects. As a result data are quoted from the
remaining 12 subjects. Following ATD, plasma total
(mean = 85.6, SD = 3.9%) and free (mean = 84.4, SD =
5.1%) tryptophan concentrations were significantly
reduced (P < 0.001). Conversely, the control drinkPage 3 of 9
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= 71.3, SD = 57.9%) tryptophan concentrations (P =
0.001). These findings are in line with previous studies
using a similar amino acid mixture [26].
Neurocognitive and mood measures
All results are presented in table 1.
There were no main effects of drink, order or interactions
on any of the VAS sub-scales. In the case of the neurocog-
nitive tests, the only main effect of drink was found on the
Trails A test which was completed significantly faster fol-
lowing ATD. Main effects of order were present for verbal
fluency and the Trails test shift-index, with the group
receiving ATD first performing significantly better on both
measures.
Interaction effects
Significant drink by order interactions were found on sev-
eral measures: WCST, perseverative errors, non-persevera-
tive errors and conceptual level responses; Stroop, colour-
word latency and interference index; Trails A, latency (see
Table 1).
On the WCST, post hoc analyses revealed that in the group
who were depleted on the second visit, significantly fewer
perseverative (z = -2.060, P = 0.039) and non-persevera-
tive (z = -2.023, P = 0.043) errors were committed, and
greater conceptual level response attained (z = -2.032, P =
0.042) following ATD. The opposite pattern emerged in
subjects depleted on their first visit, with non-persevera-
tive errors being significantly lower following the control
drink (z = -2.240, P = 0.025). Perseverative errors were
also lower (z = -1.719, P = 0.086) and conceptual level
responses higher (z = -1.334, P = 0.182) although these
results did not reach statistical significance (see figure 1).
A similar overall pattern emerged in the interactions from
the Stroop test. In subjects who were depleted on the sec-
ond visit, latencies were significantly reduced for the 'CW'
component (t = -2.712, df = 5, P = 0.042) and the interfer-
ence index (t = -2.607, df = 5, P = 0.048) following ATD.
In subjects who were depleted on the first visit, the 'CW'
latency was significantly lower following the control drink
(t = -2.333, df = 8, P = 0.048) although the difference in
the interference index did not reach significance (t = -
1.809, df = 8, P = 0.108) (See figure 2).
For the Trails A interaction, subjects who were depleted on
their second visit completed the test significantly faster
following ATD (t = -3.728, df = 5, P = 0.014), however
there was no difference in performance between drinks in
Table 1: Descriptives and ANOVA results for all measures
ATD Placebo ANOVA results †
Mean (SD) Mean (SD) Drink Order Drink × Order
WCST a
Categories completed 5.5 (1.4) 5.7 (0.8) F = 0.019, P = 0.893 F = 0.019, P = 0.893 F = 3.161, P = 0.099
Trials to complete 1st
category
12.0 (4.9) 13.6 (4.6) F = 0.996, P = 0.336 F = 0.002, P = 0.966 F = 0.183, P = 0.676
Perseverative errors (%) 9.2 (4.4) 9.1 (3.2) F = 0.112, P = 0.744 F = 1.457, P = 0.249 F = 4.712, P = 0.049 *
Non-perseverative errors
(%)
9.8 (7.3) 8.3 (4.4) F = 0.012, P = 0.887 F = 0.549, P = 0.472 F = 12.531, P = 0.004 
***
Conceptual level
responses (%)
76.8 (16.1) 79.5 (9.7) F = 0.004, P = 0.949 F = 0.902, P = 0.359 F = 7.947, P = 0.014 *
Verbal fluency
Correct 43.2 (9.2) 44.2 (9.4) F = 0.166, P = 0.690 F = 6.098, P = 0.028 * F = 0.432, P = 0.522
Stroop
C (latency; seconds) 54.1 (5.5) 54.1 (8.9) F = 0.006, P = 0.940 F = 0.007, P = 0.934 F = 0.149, P = 0.706
CW (latency; seconds) 114.0 (16.7) 112.7 (14.8) F = 0.049, P = 0.828 F = 0.079, P = 0.783 F = 11.560, P = 0.005 
***
Interference (CW – C) 59.9 (16.9) 58.7 (15.3) F = 0.022, P = 0.883 F = 0.056, P = 0.816 F = 7.615, P = 0.016 *
Trail Making
Trails A (seconds) 23.3 (5.0) 25.3 (6.5) F = 6.232, P = 0.027 * F = 0.021, P = 0.886 F = 8.680, P = 0.011 *
Trails B (seconds) 49.9 (10.4) 48.4 (9.4) F = 0.109, P = 0.746 F = 3.272, P = 0.094 F = 1.999, P = 0.181
Shift index (Trails B – A) 26.7 (11.0) 23.1 (7.4) F = 1.601, P = 0.228 F = 4.829, P = 0.047 * F = 0.008, P = 0.928
VAS mood scale
Alertness 74.0 (14.0) 71.4 (16.2) F = 0.595, P = 0.454 F = 0.905, P = 0.359 F = 3.838, P = 0.072
Contentedness 83.4 (7.5) 86.5 (7.8) F = 2.372, P = 0.147 F = 1.922, P = 0.189 F = 1.298, P = 0.275
Calmness 82.8 (12.2) 81.6 (16.4) F = 0.014, P = 0.908 F = 0.854, P = 0.372 F = 0.570, P = 0.464
† degrees of freedom = 1,13 a Results confirmed non-parametrically; see main text.Page 4 of 9
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0.740) (see figure 3).
Discussion
In this study, the effects of ATD on executive function and
subjective mood state were examined. Both free and total
plasma TRP were significantly reduced by the depletion
protocol, however no effect on mood was found. Of the
neurocognitive tests, the only main effect of drink was
found on the Trails A test, with latencies reduced by ATD
compared to the control drink. Drink by order interac-
tions were observed in outcome measures from all tests
with the exception of verbal fluency.
In our previous study in healthy volunteers [34], we found
no main effect of ATD on any measure of learning, mem-
ory or executive function. Inadequate depletion as a result
of using a less potent but more tolerable 52 g amino-acid
drink was suggested to be a possible contributory factor. A
100 g drink was used in the present study, but despite
reducing tryptophan levels by around 85%, no effects
were observed on any aspect of executive functioning
other than an improvement in visuo-motor speed and
attention (Trails A).
It has been suggested that the most accurate method of
estimating centrally available tryptophan is by defining
the percentage depletion as a ratio of tryptophan to other
large neutral amino acids (TRP/LNAA ratio) [46].
Although LNAAs were not measured in the present study,
our previous work has shown that the active 100 g amino-
acid drink significantly decreases TRP/LNAA ratios, while
this ratio remains unchanged following administration of
the control drink, despite an increase in absolute tryp-
tophan levels [28]. This protocol is also specific to 5-HT
function. The ratio of tyrosine (the precursor of
catecholamines) to other LNAAs does not change signifi-
cantly with ingestion of either drink, and thereby excludes
possible dopaminergic effects [28].
From the results of the present study it is clear that the
most consistent finding is the presence of interaction
effects in the majority of tests, although the interpretation
of such effects is somewhat complex. The most parsimo-
nious explanation is that the interaction represents a sim-
ple learning effect. As can be seen in figures 1 and 2,
subjects receiving the depleting drink on visit 2 perform
better when depleted, whereas those receiving the control
drink on visit 2 are better following the control drink. In
Drink by order interactions from the WCSTFigure 1
Drink by order interactions from the WCST Legend: A/C; Group receiving active first, control second. C/A; Group 
receiving control first, active second. †; Percentage (×101), nb. For this measure only, higher scores represent better 
performance.Page 5 of 9
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formance on the second visit irrespective of the drink
administered.
Alternatively, it is possible that 'genuine' effects of drink
may be confounded by these learning effects, when
present in the context of a crossover design. For example,
when analysed post hoc, all 6 outcome measures on which
significant interactions were observed showed signifi-
cantly improved performance following ATD when
administered on the second visit. However, in the group
which received the control drink on their second visit,
only 2 actually reached significance. This is especially
clear in the interaction on the Trails A test (figure 3). Pre-
vious studies examining the effects of ATD on executive
functions have suggested that attention may be improved
when depleted, through the removal of inhibitory actions
of 5-HT in the cortex [30,37]. Therefore, if ATD does
improve this aspect of performance, the difference would
be magnified in the group depleted on their second visit
where the effects of ATD and task familiarity would com-
bine. The opposite is also true and the effect would be
markedly attenuated in the group depleted on visit 1
when the task is novel, and the result is compared to the
'learning effect' when the control drink is administered on
visit 2.
The finding of an improvement in attentional perform-
ance (trails A) following ATD in the present study is in
keeping with the literature and the role of 5-HT [47]. What
Drink by order interactions from the Stroop testFigure 2
Drink by order interactions from the Stroop test
Drink by order interaction from the Trails (A) testFigure 3
Drink by order interaction from the Trails (A) testPage 6 of 9
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functions, especially in contrast to effects on learning and
memory. In their study Park et al [29] used a range of tests
from the CANTAB, particularly executive and visuo-spa-
tial memory and concluded that ATD elicited a deficit in
retrieval processes. However, ATD has also been shown to
impair episodic memory recall in the absence of changes
in EEG neural correlates of retrieval in healthy subjects
[35]. This suggests that ATD may affect specific stages of
information processing, namely acquisition and/or con-
solidation. There is some support for this hypothesis, as
effects have been demonstrated in other tests of long-term
memory (LTM). Schmitt et al [30] reported impaired
memory consolidation following ATD, but improved
focused attention. Riedel et al [48] found ATD impaired
several measures of long-term memory consolidation in
the absence of retrieval effects. Importantly, this effect
appeared to be highly specific and did not influence short-
term or working memory, perceptual, attentional, psycho-
motor and executive functions. This would seem to sug-
gest that the functioning of the hippocampus – which
contains a high density of 5-HT receptors – and therefore
the declarative memory system, is differentially sensitive
to the acute depletion of 5-HT in healthy subjects.
Executive tasks such as the WCST (or the analogous ID/ED
set-shift task from the CANTAB) and the Tower of London
(TOL) test of planning have been utilised in several ATD
studies with mixed results. Rogers et al [31] found impair-
ments in ID/ED reversal shifts, while Park et al [29]
reported order-dependant effects on the TOL. Our earlier
study failed to find effects on any of these tasks [34],
although we have found subtle effects in cohorts of
patients with possible vulnerabilities of the serotonergic
system [28,37]. There are several possible explanations for
this:
Firstly, Robbins [49] has suggested that performance on
these tasks is mediated by different neurotransmitter sys-
tems. Therefore manipulations affecting central catecho-
lamine systems specifically affect certain tasks sensitive to
dorsolateral prefrontal dysfunction (i.e. TOL), whereas
tasks involving reversal shifts or decision making are
dependant upon the integrity of the orbitofrontal cortex
and are sensitive to indolamine manipulation. However,
this dichotomy is not always present as can be seen in the
studies discussed previously.
A second possibility is that even in 'healthy' subjects,
some individuals may be particularly sensitive to the
effect of ATD through risk factors such as a positive family
history (FH+) of psychiatric disorder [For a review see,
[47]]. Several studies have shown small reductions in
mood following ATD in such individuals [50,51]
although there are exceptions to this, particularly with
respect to neurocognitive functioning where several stud-
ies have failed to find differential effects in FH+ subjects
[48] or in cohorts with a high proportion of FH+ [33].
This is especially problematic as studies of the effects of
ATD tend to involve small sample sizes.
A final possibility returns to our earlier suggestion that
disruption of 5-HT levels at the hippocampus may be cen-
tral to the observable effects on neurocognitive function,
even executive functions. Riedel et al [47] have speculated
that memory consolidation impairment is mediated by
the inhibiting effects of ATD on temporal regions,
especially the hippocampus, whereas the improved atten-
tional performance is mediated by enhanced fronto-
cortical arousal. However, as stated earlier, there are a
multiplicity of processes subserved by the central
executive [13] the functioning of which is linked to, but
not necessarily coterminous with, the operation of the
frontal lobes [15,16]. Executive functions activate diverse
neural circuitry forming reciprocal frontal-subcortical
loops stemming from structures such as the basal ganglia
and hippocampus, projecting forward to the frontal lobes
[14]. Animal studies have confirmed that tryptophan
depletion reduces 5-HT levels in frontal cortex [52], hip-
pocampus and striatum [53] as well as total brain levels
[54]. Therefore (executive) tasks which rely upon the
integrity of these circuits are likely to be affected differen-
tially by ATD depending upon the specific demands of the
task and possibly the particular outcome measures
derived. For example, increased frontal arousal and inhi-
bition at posterior sites may result in increased speed of
response, but with decreased accuracy, especially with
complex tasks. This is also consistent with the finding that
reduced serotonergic function in patients with personality
disorder is associated with high impulsivity [59]. There-
fore, low 5-HT levels or dysfunction at the receptor level
may underpin the symptomatic profile of impulse control
disorders, possibly through a loss of executive control.
However, this is based on very limited evidence from the
results of the present study and should be considered ten-
tatively, but may warrant examination in future research.
Furthermore, studies have demonstrated that impaired
performance on 'executive-type' tasks in Parkinson's Dis-
ease can be overcome by some individuals through a shift
to processing within the declarative memory system [55].
Conversely, in patients with frontal lobe damage who per-
form within normal limits on executive tasks, perform-
ance can be compromised if specific test instructions are
given thereby 'switching' from a relatively automatic proc-
ess to one more 'supervisory' in nature [56,57]. While the
disruption of a single neurotransmitter system through
ATD is not directly comparable to the structural damage
described above, it may be possible that some subjects arePage 7 of 9
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performance.
Conclusions
In summary, the robust nature of the amino-acid tryp-
tophan depletion paradigm has again been demonstrated.
Significant depletion of plasma TRP levels was achieved,
which had no effect on mood but speeded simple reaction
times on a test of attention in line with the findings of
many previous studies. Methodological problems limit
our understanding of the role of 5-HT in executive func-
tions. Larger studies may allow detailed analysis of the fre-
quently observed interaction effects, or parallel group
designs may be required which are not affected by carry-
over effects or task familiarity, a significant confound
when utilising tests of executive function which can be
dependant upon novelty [58].
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